Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q2 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.